TELA Bio, Inc. announced on June 3, 2025, the launch of its OviTex Inguinal Reinforced Tissue Matrix in Europe.
TELA Bio—which was founded in 2012 and is headquartered in Pennsylvania—is a medical device company that specializes in providing soft-tissue surgical products. According to TELA Bio, its soft-tissue reconstruction solutions “leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials.” In particular, Tela Bio’s OviTex portfolio uses a tissue matrix comprised of ovine rumen that is interwoven with a minimum amount of polymer to ensure durability of the mesh.
The OviTex Inguinal Reinforced Tissue Matrix is specifically designed for inguinal hernia repair, which is “probably the most common procedure in general surgery.” Inguinal hernias occur when the tissue lining either the intestine or the abdominal cavity protrudes through the abdomen. Repairing an inguinal hernia entails pushing the protruding tissue back into the abdomen and then strengthening the abdominal wall with sutures or mesh.
The European launch of the Inguinal Reinforced Tissue Matrix comes just over a year after the U.S. launch of the product in April of 2024. In the two days following the European launch of the Inguinal Reinforced Tissue Matrix, TELA Bio’s stock prices rose by over 24%.
Noting the expansion of robot-assisted procedures in Europe, TELA Bio’s president of Europe Operations, Bill Allan, said “there is great opportunity for naturally derived devices that support healing and have strong clinical data.” According to Allan, “OviTex Inguinal is purpose-built to address that need. In the European market—where shared decision-making between surgeons and patients is a hallmark of surgical planning, this product is an ideal fit. We believe it offers European surgeons a compelling option that is designed to deliver on both clinical performance and patient expectations.”
